Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Consolidated Statements of Operations
Revenues	$ 74,890	$ 71,348	$ 65,206
Cost of revenues	20,729	19,643	15,483
Gross profit	54,161	51,705	49,723
Operating expenses:
Sales and marketing	45,631	47,318	49,982
General and administrative	30,322	25,426	25,516
Research and development	12,771	9,515	9,336
Total operating expenses	88,724	82,259	84,834
Loss from operations	(34,563)	(30,554)	(35,111)
Other (income) expense:
Interest expense	7,286	5,424	4,251
Loss on extinguishment of debt	4,427
Other income, net	(2,549)	(5,789)	(2,203)
Net loss	(43,727)	(30,189)	(37,159)
Less: Non-controlling interest	19
Net loss attributable to Neuronetics stockholders'	$ (43,708)	$ (30,189)	$ (37,159)
Net loss per share of common stock outstanding, basic attributable to Neuronetics stockholders'	$ (1.38)	$ (1.05)	$ (1.38)
Net loss per share of common stock outstanding, diluted attributable to Neuronetics stockholders'	$ (1.38)	$ (1.05)	$ (1.38)
Weighted average common shares outstanding, basic	31,734	28,658	26,900
Weighted average common shares outstanding, diluted	31,734	28,658	26,900